Literature DB >> 4975656

In vitro effect of rifampin on mycobacteria.

V Lorian, M Finland.   

Abstract

Rifampin inhibited 20 strains of Mycobacterium tuberculosis in concentrations of 0.005 to 0.02 mug/ml in 7H-9 broth with Tween 80 and killed all or nearly all of the inoculum in four to eight times greater concentrations. In the same medium without Tween 80, as well as on 7H-10 agar, about 16 to 64 times these amounts were required to produce the same effect. Rifampin was also active against M. kansasii and some of the nonchromogenic mycobacteria. The incidence of mycobacterial cells resistant to rifampin within the cultures studied was in the range of one to four per 10(8) to 10(9) colony-forming units with concentrations of 4 to 125 mug of rifampin per ml. Only one of the Battey cultures and that of M. fortuitum yielded cells resistant to rifampin at 125 mug/ml but not at 500 mug/ml. The same strains yielded more than double that number of organisms resistant to streptomycin and up to 100 times more organisms resistant to isoniazid. All three drugs stopped the growth or reduced the mycobacterial population in growing cultures after contact for 24 to 48 hr. Complete inhibition of growth was produced by rifampin at 1.0 mug/ml in an average of 6 days and by streptomycin at 5.0 mug/ml in 3 days. After an average contact of 10.7 days with rifampin, five of seven strains resumed growth and all strains began regrowth after exposure to streptomycin for 9.4 days. The marked susceptibility of M. tuberculosis and of atypical mycobacteria to rifampin in vitro and the relatively low incidence of resistant mutants suggests that this agent may have clinical usefulness in the treatment of tuberculosis and some other mycobacterioses.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4975656      PMCID: PMC377649          DOI: 10.1128/am.17.2.202-207.1969

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  6 in total

1.  Comparison of the antibacterial activity of rifampicin and other antibiotics.

Authors:  W R McCabe; V Lorian
Journal:  Am J Med Sci       Date:  1968-10       Impact factor: 2.378

2.  Rifampicin: a new rifamycin. I. Bacteriological studies.

Authors:  V Arioli; R Pallanza; S Furesz; G Carniti
Journal:  Arzneimittelforschung       Date:  1967-05

Review 3.  Chemical modifications and biological properties of rifamycins.

Authors:  P Sensi; N Maggi; S Füresz; G Maffii
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

4.  The antimycobacterial activity of rifampin.

Authors:  G L Hobby; T F Lenert
Journal:  Am Rev Respir Dis       Date:  1968-04

5.  [On a new class of bactericidal antibiotics with special reference to rifampicin].

Authors:  F Kradolfer
Journal:  Schweiz Med Wochenschr       Date:  1968-04-20
  6 in total
  11 in total

Review 1.  Infectious diseases: annual review of significant publications.

Authors:  H A Reimann
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

2.  Comparison of antibacterial and antiimmune effects of certain rifamycins.

Authors:  J E Kasik; M Monick
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 3.  Actions of the rifamycins.

Authors:  W Wehrli; M Staehelin
Journal:  Bacteriol Rev       Date:  1971-09

Review 4.  Rifampicin: a review.

Authors: 
Journal:  Drugs       Date:  1971       Impact factor: 9.546

5.  Susceptibility of mycobacteria to rifampin.

Authors:  C L Woodley; J O Kilburn; H L David; V A Silcox
Journal:  Antimicrob Agents Chemother       Date:  1972-10       Impact factor: 5.191

6.  Rifampin in the treatment of pulmonary tuberculosis.

Authors:  L Hyde
Journal:  Calif Med       Date:  1972-12

7.  In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum.

Authors:  E Goldstein; M C Eagle; M L LaCasse
Journal:  Appl Microbiol       Date:  1971-09

8.  In vitro susceptibility of atypical mycobacteria to rifampin.

Authors:  A Molavi; L Weinstein
Journal:  Appl Microbiol       Date:  1971-07

9.  Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate.

Authors:  Vânia Vilas-Boas; Renata Silva; Andreia Palmeira; Emília Sousa; Luísa Maria Ferreira; Paula Sério Branco; Félix Carvalho; Maria de Lourdes Bastos; Fernando Remião
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

10.  Sub-national TB prevalence surveys in India, 2006-2012: Results of uniformly conducted data analysis.

Authors:  V K Chadha; Sharda M Anjinappa; Paresh Dave; Kiran Rade; D Baskaran; P Narang; C Kolappan; K Katoch; S K Sharma; V G Rao; A N Aggarwal; P Praseeja; R Jitendra; S Swaminathan
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.